Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics has two commercial products, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, which is partnered with Bausch Health Companies, Inc.; and AZEDRA, for the treatment of unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy.
|Headquarters||New York, New York|
|Number of employees||51-200 employees|
Top 5 Recent Tweets
|January 21, 2022||ProgenicsCB||We've updated our prices, check out the Fees section on our website for more details. https://t.co/Ka8Jk9HGkY… https://t.co/yE8Q5G4CUx|